1. Home
  2. BCDA vs JNVR Comparison

BCDA vs JNVR Comparison

Compare BCDA & JNVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • JNVR
  • Stock Information
  • Founded
  • BCDA N/A
  • JNVR 2018
  • Country
  • BCDA United States
  • JNVR United States
  • Employees
  • BCDA N/A
  • JNVR N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • JNVR Finance: Consumer Services
  • Sector
  • BCDA Health Care
  • JNVR Finance
  • Exchange
  • BCDA Nasdaq
  • JNVR Nasdaq
  • Market Cap
  • BCDA 9.4M
  • JNVR 8.9M
  • IPO Year
  • BCDA N/A
  • JNVR 2023
  • Fundamental
  • Price
  • BCDA $2.87
  • JNVR $0.76
  • Analyst Decision
  • BCDA Strong Buy
  • JNVR
  • Analyst Count
  • BCDA 1
  • JNVR 0
  • Target Price
  • BCDA $60.00
  • JNVR N/A
  • AVG Volume (30 Days)
  • BCDA 85.3K
  • JNVR 1.0M
  • Earning Date
  • BCDA 08-07-2024
  • JNVR 07-30-2024
  • Dividend Yield
  • BCDA N/A
  • JNVR N/A
  • EPS Growth
  • BCDA N/A
  • JNVR N/A
  • EPS
  • BCDA N/A
  • JNVR N/A
  • Revenue
  • BCDA $468,000.00
  • JNVR $1,947,052.00
  • Revenue This Year
  • BCDA N/A
  • JNVR N/A
  • Revenue Next Year
  • BCDA $436.41
  • JNVR N/A
  • P/E Ratio
  • BCDA N/A
  • JNVR N/A
  • Revenue Growth
  • BCDA N/A
  • JNVR N/A
  • 52 Week Low
  • BCDA $2.62
  • JNVR $0.70
  • 52 Week High
  • BCDA $34.80
  • JNVR $5.50
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 36.31
  • JNVR 40.68
  • Support Level
  • BCDA $2.85
  • JNVR $0.72
  • Resistance Level
  • BCDA $3.66
  • JNVR $0.80
  • Average True Range (ATR)
  • BCDA 0.30
  • JNVR 0.09
  • MACD
  • BCDA 0.07
  • JNVR 0.00
  • Stochastic Oscillator
  • BCDA 8.65
  • JNVR 12.47

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About JNVR Janover Inc.

Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from transaction fees.

Share on Social Networks: